479422-22-5Relevant academic research and scientific papers
Inhibition of cytosolic phospholipase A2α: Hit to lead optimization
McKew, John C.,Foley, Megan A.,Thakker, Paresh,Behnke, Mark L.,Lovering, Frank E.,Sum, Fuk-Wah,Tam, Steve,Wu, Kun,Shen, Marina W. H.,Zhang, Wen,Gonzalez, Mario,Liu, Shanghao,Mahadevan, Anu,Sard, Howard,Khor, Soo Peang,Clark, James D.
, p. 135 - 158 (2007/10/03)
Compound 1 was previously reported to be a potent inhibitor of cPLA 2α in both artificial monomeric substrate and cell-based assays. However, 1 was inactive in whole blood assays previously used to characterize cyclooxygenase and lipoxygenase inhibitors. The IC50 of 1 increased dramatically with cell number or lipid/detergent concentration. In an attempt to insert an electrophilic ketone between the indole and benzole acid moieties, we discovered that increasing the distance between the two moieties gave a compound with activity in the GLU (7-hydroxycoumarinyl-γ- linolenate) micelle assay, which contains lipid and detergent. Extensive structure-activity relationship work around this lead identified a potent pharmacophore for cPLA2α inhibition. The IC50s between the GLU micelle and rat whole blood assays correlated highly. No correlation was found for other parameters, including lipophilicity or acidity of the required acid functionality. Compounds 25, 39, and 94 emerged as potent, selective inhibitors of cPLA2α and represent well-validated starting points for further optimization.
Inhibitors of phospholipase enzymes
-
, (2008/06/13)
This invention concerns compounds and pharmaceutical compositions useful for treating or preventing inflammatory conditions in a mammal, the methods comprising administration of novel pharmaceutically useful compounds of the general formulae: or pharmaceutically acceptable salts thereof, wherein R1-R5are as defined in the specification.
